From baseline to 24 weeks the change in LDLC 488 for alirocumab vs 91 for placebo p lt 00001 The dose of alirocumab was uptitrated in 434 of participants this reduction was maintained to 52 ID: 932827
Download Presentation The PPT/PDF document "ODYSSEY FH I and II In FH I:" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
ODYSSEY FH I and II
In FH I:
From baseline to 24 weeks, the change in
LDL-C: -48.8% for alirocumab vs. 9.1% for placebo (p < 0.0001). The dose of alirocumab was up-titrated in 43.4% of participants; this reduction was maintained to 52 weeks In FH II: From baseline to 24 weeks, the change in LDL-C: -48.7% for alirocumab vs. 2.8% for placebo (p < 0.0001). The dose of alirocumab was up-titrated in 38.6% of participants; this reduction was maintained to 52 weeks
Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ injection (up-titration possible to 150 mg) every 2 weeks (n = 490) vs. placebo SQ injection every 2 weeks (n = 245).
Results
Conclusions
Among patients with heterozygous familial hypercholesterolemia, alirocumab resulted in a large reduction in LDL-C compared with placebo, which was maintained to 52 weeks
Presented by Dr. John Kastelein at ESC 2014
(p
< 0.0001)
Alirocumab
%
-48.8
9.1
Placebo
Percent change in LDL-C from baseline to 24 weeks
-48.7
2.8
(p
< 0.0001)
FH I
FH II